Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Targeting Human Central Nervous System Protein Kinases: An Isoform Selective p38αMAPK Inhibitor That Attenuates Disease Progression in Alzheimer's Disease Mouse Models

  • Saktimayee M. Roy
  • , Valerie L. Grum-Tokars
  • , James P. Schavocky
  • , Faisal Saeed
  • , Agnieszka Staniszewski
  • , Andrew F. Teich
  • , Ottavio Arancio
  • , Adam D. Bachstetter
  • , Scott J. Webster
  • , Linda J. Van Eldik
  • , George Minasov
  • , Wayne F. Anderson
  • , Jeffrey C. Pelletier
  • , D. Martin Watterson

Producción científica: Articlerevisión exhaustiva

89 Citas (Scopus)

Resumen

The first kinase inhibitor drug approval in 2001 initiated a remarkable decade of tyrosine kinase inhibitor drugs for oncology indications, but a void exists for serine/threonine protein kinase inhibitor drugs and central nervous system indications. Stress kinases are of special interest in neurological and neuropsychiatric disorders due to their involvement in synaptic dysfunction and complex disease susceptibility. Clinical and preclinical evidence implicates the stress related kinase p38αMAPK as a potential neurotherapeutic target, but isoform selective p38αMAPK inhibitor candidates are lacking and the mixed kinase inhibitor drugs that are promising in peripheral tissue disease indications have limitations for neurologic indications. Therefore, pursuit of the neurotherapeutic hypothesis requires kinase isoform selective inhibitors with appropriate neuropharmacology features. Synaptic dysfunction disorders offer a potential for enhanced pharmacological efficacy due to stress-induced activation of p38αMAPK in both neurons and glia, the interacting cellular components of the synaptic pathophysiological axis, to be modulated. We report a novel isoform selective p38αMAPK inhibitor, MW01-18-150SRM (=MW150), that is efficacious in suppression of hippocampal-dependent associative and spatial memory deficits in two distinct synaptic dysfunction mouse models. A synthetic scheme for biocompatible product and positive outcomes from pharmacological screens are presented. The high-resolution crystallographic structure of the p38αMAPK/MW150 complex documents active site binding, reveals a potential low energy conformation of the bound inhibitor, and suggests a structural explanation for MW150's exquisite target selectivity. As far as we are aware, MW150 is without precedent as an isoform selective p38MAPK inhibitor or as a kinase inhibitor capable of modulating in vivo stress related behavior. (Graph Presented).

Idioma originalEnglish
Páginas (desde-hasta)666-680
Número de páginas15
PublicaciónACS Chemical Neuroscience
Volumen6
N.º4
DOI
EstadoPublished - abr 15 2015

Nota bibliográfica

Publisher Copyright:
© 2015 American Chemical Society.

Financiación

FinanciadoresNúmero del financiador
National Institutes of Health (NIH)R01AG031311
National Institute on AgingU01AG043415

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • Biochemistry
    • Physiology
    • Cognitive Neuroscience
    • Cell Biology

    Huella

    Profundice en los temas de investigación de 'Targeting Human Central Nervous System Protein Kinases: An Isoform Selective p38αMAPK Inhibitor That Attenuates Disease Progression in Alzheimer's Disease Mouse Models'. En conjunto forman una huella única.

    Citar esto